Natera initiated with an Equal Weight at Wells Fargo

Wells Fargo analyst Brandon Couillard initiated coverage of Natera (NTRA) with an Equal Weight rating and $175 price target The firm’s enthusiasm for Signatera’s growth potential in molecular residual disease is offset by less conviction in Natera’s margin and cash flow outlook. Trading at 10-times revenue, Natera’s valuation implies a rich multiple for oncology, the analyst tells investors in a research note. Wells tells investors to wait for a better entry point.